Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 3
2009 2
2010 3
2011 1
2012 2
2013 1
2014 1
2015 1
2016 3
2017 4
2018 10
2019 20
2020 26
2021 28
2022 30
2023 24
2024 30
2025 28
2026 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

199 results

Results by year

Filters applied: . Clear all
Page 1
Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis.
Guglielmetti L, Khan U, Velásquez GE, Gouillou M, Abubakirov A, Baudin E, Berikova E, Berry C, Bonnet M, Cellamare M, Chavan V, Cox V, Dakenova Z, de Jong BC, Ferlazzo G, Karabayev A, Kirakosyan O, Kiria N, Kunda M, Lachenal N, Lecca L, McIlleron H, Motta I, Toscano SM, Mushtaque H, Nahid P, Oyewusi L, Panda S, Patil S, Phillips PPJ, Ruiz J, Salahuddin N, Garavito ES, Seung KJ, Ticona E, Trippa L, Vasquez DEV, Wasserman S, Rich ML, Varaine F, Mitnick CD; endTB Clinical Trial Team. Guglielmetti L, et al. N Engl J Med. 2025 Jan 30;392(5):468-482. doi: 10.1056/NEJMoa2400327. N Engl J Med. 2025. PMID: 39879593 Free PMC article. Clinical Trial.
Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial.
Guglielmetti L, Khan U, Velásquez GE, Gouillou M, Ali MH, Amjad S, Kamal F, Abubakirov A, Ardizzoni E, Baudin E, Bektassov S, Berry C, Bonnet M, Chavan V, Coutisson S, Dakenova Z, de Jong BC, Dinh LV, Ferlazzo G, Kirakosyan O, Lachenal N, Lecca L, McIlleron H, Mikanda KK, Mucching-Toscano S, Mulders W, Mushtaque H, Nahid P, Nguyen DV, Nguyen NV, Oyewusi L, Motta I, Panda S, Patil S, Pham TH, Phan DT, Phan HTT, Phillips PPJ, Ruiz J, Rupasinghe P, Salahuddin N, Sanchez-Garavito E, Seung KJ, Asfaw MT, Vargas Vasquez D, Rich ML, Varaine F, Mitnick CD; endTB-Q Clinical Trial Team. Guglielmetti L, et al. Lancet Respir Med. 2025 Sep;13(9):809-820. doi: 10.1016/S2213-2600(25)00194-8. Epub 2025 Jul 16. Lancet Respir Med. 2025. PMID: 40683298 Free article. Clinical Trial.
2-(3,4-Dimethyl-anilino)acetohydrazide.
Salim M, Mahmood Z, Tahir MN, Ahmad S, Yaseen M. Salim M, et al. Among authors: yaseen m. Acta Crystallogr Sect E Struct Rep Online. 2009 Sep 30;65(Pt 10):o2595. doi: 10.1107/S1600536809038963. Acta Crystallogr Sect E Struct Rep Online. 2009. PMID: 21578030 Free PMC article.
The potential of H5N1 viruses to adapt to bovine cells varies throughout evolution.
Turnbull ML, Zakaria MK, Upfold NS, Bakshi S, Magill C, Das UR, Clarke AT, Mojsiejczuk L, Herder V, Dee K, Liu N, Folwarczna M, Ilia G, Furnon W, Schultz V, Chen H, Devlin R, McCowan J, Young AL, Po WW, Smollett K, Yaseen MA, Ross R, Bhide A, van Kekem B, Fouchier RAM, da Silva Filipe A, Iqbal M, Roberts E, Hughes J, Werling D, Murcia PR, Palmarini M. Turnbull ML, et al. Among authors: yaseen ma. Nat Commun. 2025 Dec 15;16(1):11042. doi: 10.1038/s41467-025-67234-1. Nat Commun. 2025. PMID: 41398153 Free PMC article.
Journal update monthly top five.
Charlton-Webb J, Hosfield T, Marshall C, Yaseen M, Gardner L, Guha T, Welman K, Prager G. Charlton-Webb J, et al. Among authors: yaseen m. Emerg Med J. 2025 Sep 24;42(10):686-687. doi: 10.1136/emermed-2025-215495. Emerg Med J. 2025. PMID: 40992906 No abstract available.
199 results